BRAF inhibition and the spectrum of granulomatous reactions.

Abstract excerpt

V-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors have emerged as a promising targeted therapy for malignancies with BRAF mutations, particularly metastatic melanoma. However, granulomatous reactions (GRs), including sarcoidosis and sarcoid-like reactions, have been reported as a consequence of BRAF inhibition. It is important to adequately characterize these GRs, including cutaneous manifestations...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Melanoma
• Share to Mice
• Share to Mutation